| Hazard Information | Back Directory | [Uses]
Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity Ki of 2.8 μM[1][2]. | [in vivo]
Belapectin (2.4 mg/mouse; i.p.; 3 times per week for 3 weeks) only exerts function under the combination with anti-OX40 mAb, does cause a significant reduction in tumor growth and a corresponding increase in survival. The combined treatment also produces lasting long-term memory, and 100 percent of the tumor-free mice were protected from subsequent tumor reattacks[1].
| Animal Model: | Wild-type C57BL/6 and BALB/c mice[1] | | Dosage: | 2.4 mg/mouse, accompanied with anti-OX40 mAb (250 μg) | | Administration: | Intraperitoneal injection; 3 times per week for 3 weeks | | Result: | Inhibited tumor growth.
Enhanced the efficacy of checkpoint blockade (aPD-L1) immunotherapy. |
| [IC 50]
Galectin-3 | [References]
[1] Sturgill ER, et al. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Oncoimmunology. 2021 Mar 1;10(1):1892265. DOI:10.1080/2162402X.2021.1892265
[2] Capasso D, et al. Galectins detection for the diagnosis of chronic diseases: An emerging biosensor approach[J]. TrAC Trends in Analytical Chemistry, 2023: 116952. |
|
|